References
- Bernard N., Cuisinaud G., Jozefczak C., Seccia M., Ferry N., Sassard J. Sensitive gas chromatographic method for the determination in plasma of FM 24, 1-(2-exo-bicyclo[2,2,1]hept-2-ylphenoxy)-3-[(1-methylethyl amino]2-propanol, a new β-adrenoceptor blocking agent. Journal of Chromatography 1980; 183: 99–103
- Borgström L., Johansson C.-G., Larsson H., Lenander R. Pharmacokinetics of propranolol. Journal of Pharmacokinetics and Biopharmaceutics 1981; 9: 419–429
- Cheymol G., Jaillon P., Lecoq V., Cheymol A., Krumenacker M. Cardiovascular bêta-adrenergic blocking effects of bornaprolol in man; relationship to dose and plasma concentration. Journal of Cardiovascular Pharmacology 1987; 9: 694–698
- d'Athis P. H., Richard M.-O., De Lauture D., Rey E., Bouvier-D'Yvoire M., Clément E., Olive G. Etude comparative des biodisponibilités de deux formes de spironolactone. Thérapie 1981; 36: 443–449
- Giudicelli J. F., Witchitz S. Les bêta-bloquants. Semaine des Hôpitaux, Paris 1983; 34: 2395–2426
- Le Fur G., Canton T., Malgouris C., Paillard J.J., Hardy J. C., Gueremy C., Uzan A. Stereospecificity of the in vitro and in vivo blockade of β-receptors by FM 24, a slowly reversible ligand. Life Sciences 1981; 29: 2481–2489
- Le Fur G., Paillard J. J., Rougeot C., Uzan A. Tissue levels and displacement of in vivo labelled β-adrenergic receptors by FM 24, an irreversible or slowly dissociable β-blocker. European Journal of Pharmacology 1980; 67: 13–418
- Le Fur G., Schmelck Ph., Geynet P., Hanoune J., Uzán A. Cardiac beta-adrenergic receptor: evaluation of FM 24 as a new and very slowly dissociable blocker. Life Sciences 1978; 23: 1841–1850
- Mestre M., Le Fur G., Uzan A. Long acting effect of 1-2-(exo-bicyclo[2,2,1]hept-2-ylphenoxy)-3-[(1-methylethyl)amino]-2-propanol hydrochloride (FM 24), a new β-blocking agent. Proceedings, 7th International Congress of Pharmacology, IUPHAR. Pergamon Press, Oxford 1978; 961, Abstr, 2912
- Walle T., Fagan T.-C., Conradi E.-C., Walle U.-K., Gaffney T.-E. Presystemic and systemic glucuronidation of propranolol. Clinical Pharmacology and Therapeutics 1979; 26: 167–172
- Zopitar Z., Vrhova B., Lenardič A., Cvelbar P., Žorž M., Francetič I. Dose-dependent bioavailability of propranolol. International Journal of Clinical Pharmacology 1986; 24: 319–322